Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer.
Liposomes are potential drug carriers for pulmonary drug delivery: They can be prepared from phospholipids, which are endogenous to the respiratory tract as a component of pulmonary surfactant, and at an appropriate dose liposomes do not pose a toxicological risk to this organ. Among the various categories of drug that benefit from liposomal entrapment is the anti-inflammatory enzyme superoxide dismutase, thus prolonging its biological half-life. The delivery of liposomes by nebulization is hampered by stability problems, like physical and chemical changes that may lead to chemical degradation and leakage of the encapsulated drug. Here we present data of liposomes aerosolized with a novel electronic nebulizer based on a vibrating membrane technology (PARI eFlow), which amends drawbacks like liposomes degradation and product release. The data acquisition included aerosol properties such as aerodynamic particle size, nebulization efficiency, and liposome leakage upon nebulization. In conclusion, this study shows the ability of the PARI eFlow to nebulize high amounts of liposomal recombinant human superoxide dismutase with reduced vesicle disruption tested in an enclosing experimental protocol.
Wagner
A
A
Polymun Scientific, Immunbiologische Forschung GmbH, Vienna, Austria. Andreas.Wagner@boku.ac.at
Vorauer-Uhl
K
K
Katinger
H
H
D000336:Aerosols; D016503:Drug Delivery Systems; D004355:Drug Stability; D004795:Enzyme Stability; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D013314:Stress, Mechanical; D013482:Superoxide Dismutase / Q000737:chemistry*; D014732:Vibration
D000336:Aerosols; D008081:Liposomes; D013482:Superoxide Dismutase